Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Pallavi Mishra-Kalyani"'
Autor:
David J. Pinato, Xiaoxue Li, Pallavi Mishra-Kalyani, Antonio D’Alessio, Claudia A.M. Fulgenzi, Bernhard Scheiner, Matthias Pinter, Guo Wei, Julie Schneider, Donna R. Rivera, Richard Pazdur, Marc R. Theoret, Sandra Casak, Steven Lemery, Lola Fashoyin-Aje, Alessio Cortellini, Lorraine Pelosof
Publikováno v:
JHEP Reports, Vol 5, Iss 6, Pp 100747- (2023)
Background & Aims: Immune checkpoint inhibitors (ICIs) alone or in combination with other ICIs or vascular endothelial growth factor pathway inhibitors are therapeutic options in unresectable/metastatic hepatocellular carcinoma (HCC). Whether antibio
Externí odkaz:
https://doaj.org/article/6927577eae4849a9b007d6bf4469b648
Autor:
Martin Ho, Susan Gruber, Yixin Fang, Douglas E. Faris, Pallavi Mishra-Kalyani, David Benkeser, Mark van der Laan
Publikováno v:
Statistics in Biopharmaceutical Research. :1-14
Autor:
Kwan Lee, Weili He, Frank W. Rockhold, Roseann White, Telba Irony, Zhaoling Meng, Mark J. van der Laan, Qi Jiang, Xiwu Lin, Pallavi Mishra-Kalyani, Hana Lee, JC Chen, Yixin Fang, Hong-Wei Wang, Yang Song, Martin Ho
Publikováno v:
Statistics in Biopharmaceutical Research. 15:43-56
As real-world data (RWD) become more readily available, the regulatory agencies, medical product developers, and other key stakeholders have increasing interests in exploring the use of real-world ...
Autor:
Hana Lee, Kwan Lee, Mark J. van der Laan, Benjamin A. Goldstein, JC Chen, Weili He, Hong-Wei Wang, Frank W. Rockhold, Zhaoling Meng, Xiwu Lin, Yixin Fang, Qi Jiang, Pallavi Mishra-Kalyani, Martin Ho, Roseann White, Telba Irony, Yang Song
Publikováno v:
Statistics in Biopharmaceutical Research. 15:29-42
Real-world data (RWD), such as electronic health records, reimbursement requests as adjudicated by health insurance companies, and health survey data as collected by government agencies or other re...
Autor:
Arup Kumar Sinha, Olen Stephens, Marc R. Theoret, Mei Ou, R. Pazdur, Gregory H. Reaman, Katherine Windsor, Yuching Yang, Suzanne Demko, Denise Casey, Kirsten B. Goldberg, Harpreet Singh, Abhilasha Nair, Jianghong Fan, Yuan Li Shen, Ruby Leong, Whitney S. Helms, M. Anwar Goheer, Byeongtaek Oh, Jiang Liu, Vishal Bhatnagar, Sachia Khasar, Selena R. Daniels, Stacy Shifflett Shord, Sharon Sickafuse, Lili Pan, Yuan Xu, Pallavi Mishra-Kalyani
Publikováno v:
Clinical Cancer Research. 27:4142-4146
On April 10, 2020, the FDA approved selumetinib (KOSELUGO, AstraZeneca) for the treatment of pediatric patients 2 years of age and older with neurofibromatosis type 1 who have symptomatic, inoperable plexiform neurofibromas. Approval was based on dem
Autor:
Frank W. Rockhold, Richard C. Zink, Yixin Fang, JC Chen, Pallavi Mishra-Kalyani, Weili He, Martin Ho, Douglas E. Faries, Kwan Lee, Benjamin A. Goldstein, Hong-Wei Wang, Mark Levenson
Publikováno v:
Statistics in Biopharmaceutical Research. 15:3-13
Real-world evidence (RWE), derived from data from “real-world” clinical practice and medical product utilization, is an increasingly important source of evidence that holds great potential to incre...
Autor:
Felice Yang, Oladimeji Akinboro, Catherine Lerro, Fatima Rizvi, Pallavi Mishra-Kalyani, Paul G. Kluetz, Harpreet Singh, Donna R. Rivera
Publikováno v:
Cancer Research. 83:A025-A025
Background: Small cell lung cancer (SCLC) is an aggressive form of cancer characterized by rapid progression, early metastases, and poor prognosis. Clinical trials (CTs) leading to approval of various classes of medical products have recently increas
Autor:
Felice Yang, Jonathon Vallejo, Oladimeji Akinboro, Catherine Lerro, Pallavi Mishra-Kalyani, Shenghui Tang, Paul G. Kluetz, Harpreet Singh, Donna R. Rivera
Publikováno v:
Cancer Research. 83:A024-A024
Background: Lung cancer is frequently diagnosed in older adults. As the U.S. population continues to age, understanding treatment effects in lung cancer patients ≥65 years of age is increasingly important. Despite this trend, clinical trials (CTs)